Biomarker effectively screens for colorectal cancer utilizing a simple enzyme-linked immunosorbent assay Edmonton, AB | March 11, 2020 Bertech has completed initial pivotal trials of its blood-based enzyme-linked immunosorbent assay (ELISA) which utilizes its proprietary protein biomarker to screen and diagnose for colorectal cancer (CRC). Initial results from the trials show the novel
Bertech Pharma Ltd. announced today that Dr. David Durack has joined its Scientific Advisory Board. “The addition of Dr. Durack will further diversify the outstanding talents and wide‐ranging experience that our Scientific Advisory Board already brings to Bertech,” said Mr. Bern Philip, President and CEO of Bertech Pharma. . “Dr
Bertech Pharma Ltd. announced today that Dr. David Evans and Dr. Randy Johnson have joined its Scientific Advisory Board. “The addition of Dr. Evans and Dr. Johnson to Bertech’s Scientific Board of Advisors brings significant scientific experience to Bertech and will assist in moving its cancer development programs forward,” said
